FREEDOM OF INFORMATION SUMMARY
ORIGINAL ABBREVIATED NEW ANIMAL DRUG APPLICATION

ANADA 200-721
Midamox™ for Cats
(imidacloprid + moxidectin)
Topical Solution
Cats

Midamox™ for Cats is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis*. Midamox™ for Cats kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment of flea infestations. Midamox™ for Cats is also indicated for the treatment and control of ear mite (*Otodectes cynotis*) infestations and the following intestinal parasites:

<table>
<thead>
<tr>
<th>Intestinal Parasite</th>
<th>Intestinal Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adult</td>
</tr>
<tr>
<td>Hookworm Species</td>
<td><em>Ancylostoma tubaeforme</em></td>
</tr>
<tr>
<td>Roundworm Species</td>
<td><em>Toxocara cati</em></td>
</tr>
</tbody>
</table>

Sponsored by:
Norbrook Laboratories, Ltd.
Table of Contents

I. GENERAL INFORMATION ............................................................................................................. 3
II. BIOEQUIVALENCE .................................................................................................................. 4
III. HUMAN FOOD SAFETY ......................................................................................................... 5
IV. USER SAFETY ......................................................................................................................... 5
V. AGENCY CONCLUSIONS ......................................................................................................... 5
I. GENERAL INFORMATION

A. File Number

ANADA 200-721

B. Sponsor

Norbrook Laboratories, Ltd.
Carnbane Industrial Estate
Newry, County Down
BT35 6QQ UNITED KINGDOM

Drug Labeler Code: 055529

U.S. Agent Name and Address:
Melanie Archer
Norbrook, Inc.
9401 Indian Creek Parkway
Suite 680
Overland Park, KS 66210

C. Proprietary Name

Midamox™ for Cats

D. Drug Product Established Name

imidacloprid + moxidectin

E. Pharmacological Category

Antiparasitic

F. Dosage Form

Topical solution

G. Amount of Active Ingredient

100 mg/mL (10%) imidacloprid and 10 mg/mL (1%) moxidectin

H. How Supplied

0.23 mL applicator: 3 applicators per carton
0.4 mL and 0.8 mL applicators: 6 applicators per carton

I. Dispensing Status

Prescription (Rx)
J. Dosage Regimen

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.

<table>
<thead>
<tr>
<th>Cat (lbs.)</th>
<th>Midamox for Cats</th>
<th>Volume (mL)</th>
<th>Imidacloprid (mg)</th>
<th>Moxidectin (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-5</td>
<td>Midamox 5</td>
<td>0.23</td>
<td>23</td>
<td>2.3</td>
</tr>
<tr>
<td>5.1-9</td>
<td>Midamox 9</td>
<td>0.4</td>
<td>40</td>
<td>4</td>
</tr>
<tr>
<td>9.1-18*</td>
<td>Midamox 18</td>
<td>0.8</td>
<td>80</td>
<td>8</td>
</tr>
</tbody>
</table>

*Cats over 18 lbs. should be treated with the appropriate combination of Midamox for Cats applicators.

K. Route of Administration

Topical

L. Species/Class

Cats

M. Indications

Midamox™ for Cats is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis*. Midamox™ for Cats kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment of flea infestations. Midamox™ for Cats is also indicated for the treatment and control of ear mite (*Otodectes cynotis*) infestations and the following intestinal parasites:

<table>
<thead>
<tr>
<th>Intestinal Parasite</th>
<th>Intestinal Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adult</td>
</tr>
<tr>
<td>Hookworm Species</td>
<td></td>
</tr>
<tr>
<td><em>Ancylostoma tubaeforme</em></td>
<td>X</td>
</tr>
<tr>
<td>Roundworm Species</td>
<td></td>
</tr>
<tr>
<td><em>Toxocara cati</em></td>
<td>X</td>
</tr>
</tbody>
</table>

N. Reference Listed New Animal Drug (RLNAD)

advantage multi™ for cats; imidacloprid + moxidectin; NADA 141-254; Elanco US Inc.

II. BIOEQUIVALENCE

The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Generic Animal Drug and Patent Term Restoration Act (GADPTRA) of 1988, allows for an abbreviated new animal drug application (ANADA) to be submitted for a generic version of an approved new animal drug (RLNAD). The ANADA sponsor is required to show that the generic product is bioequivalent to the RLNAD, which has been shown to be safe and effective. Effectiveness, target animal safety and human food safety data (other than tissue residue data) are not required for approval of an ANADA. If bioequivalence is demonstrated through a clinical endpoint study in a food-producing
animal, then a tissue residue study to establish the withdrawal period for the generic product is also required. For certain dosage forms, the agency will grant a waiver from the requirement to perform in vivo bioequivalence studies (biowaiver) (55 FR 24645, June 18, 1990; Fifth GADPTRA Policy Letter; Bioequivalence Guideline, October 9, 2002).

Based on the formulation characteristics of the generic product, Norbrook Laboratories, Ltd., was granted a biowaiver for the generic product Midamox™ for Cats (imidacloprid + moxidectin) topical solution. The generic drug product is a topical solution, contains the same active ingredient in the same concentration and dosage form as the RLNAD, and contains no inactive ingredients that may significantly affect the bioavailability of the active ingredient. The RLNAD is advantage multi™ for cats (imidacloprid + moxidectin) topical solution, sponsored by Elanco US Inc., under NADA 141-254, and was approved for use in cats on January 19, 2007.

III. HUMAN FOOD SAFETY

This drug is intended for use in cats. Because this new animal drug is not intended for use in food-producing animals, CVM did not require data pertaining to drug residues in food (i.e., human food safety) for approval of this ANADA.

IV. USER SAFETY

The product labeling contains the following information regarding safety to humans handling, administering, or exposed to Midamox™ for Cats:

Not for human use. Keep out of the reach of children. Children should not come in contact with the application site for 30 minutes after application.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin. Wash hands thoroughly with soap and warm water after handling. If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice. The Safety Data Sheet (SDS) provides additional occupational safety information. For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call 1-866-591-5777.

V. AGENCY CONCLUSIONS

The data submitted in support of this ANADA satisfy the requirements of section 512(c)(2) of the FD&C Act. The data demonstrate that Midamox™ for Cats when used according to the label, is safe and effective for the indications listed in Section I.M. above.